Skip to main content

Advertisement

SpringerLink
Log in

Systemtherapie beim fortgeschrittenen Leberzellkarzinom

Immunonkologische Optionen und differenzierte Therapieentscheidungen

  • Gastroonkologie
  • Fortbildung
  • Published:
Im Fokus Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Villanueva A. Hepatocellular carcinoma. New Engl J Med. 2019;380(15):1450-62

  2. S3-Leitlinie Diagnostik und Therapie des Hepatozellulären Karzinoms und biliärer Karzinome. AWMF-Registernr.: 032 - 053OL

  3. Finn RS et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. New Engl J Med. 2020;382(20):1894-905

  4. Cheng AL et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862-73

  5. Fulgenzi CAM et al. Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study. Eur J Cancer. 2022;175:204-13

  6. D‘Alessio A et al. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. Hepatology. 2022;76(4):1000-12

  7. Fründt TW et al. Equal efficacy and safety profile in elderly patients with hepatocellular carcinoma receiving palliative treatment. Cancers (Basel). 2022;14(3):768

  8. Abou-Alfa GK et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evid. 2022;1(8):DOI10.1056/EVIDoa2100070

  9. Llovet JM et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(12):1399-410

Download references

Author information

Authors and Affiliations

  1. Klinik für Allgemeine Innere Medizin, Onkologie/Hämatologie, Gastroenterologie und Infektiologie, Klinikum Esslingen - Cancer Center Esslingen, Hirschlandstraße 97, 73730, Esslingen, Deutschland

    Henning Wege

Authors
  1. Pamela Proissl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guido Hausner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Henning Wege
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Henning Wege.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Proissl, P., Hausner, G. & Wege, H. Systemtherapie beim fortgeschrittenen Leberzellkarzinom. Fokus Onkol 27, 15–18 (2024). https://doi.org/10.1007/s15015-024-3734-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-024-3734-4

Search

Navigation